Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis

Vaccine
Duzhang ZhuGary Zlotnick

Abstract

Neisseria meningitidis is a major cause of bacterial meningitis in the human population, especially among young children. There is a need to develop a non-capsular vaccine to prevent meningococcal B infections due to the inadequate immune response elicited against the capsular polysaccharide of these strains. Previously, we developed a Swiss Webster adult mouse intranasal challenge model for group B N. meningitidis and evaluated several potential vaccine candidates including a meningococcal outer membrane protein, P2086, through parenteral immunization. Since N. meningitidis is a respiratory pathogen, a mucosal immune response may play an important role in the defense against meningococcal infections. Thus, intranasal immunization may be more effective than traditional parenteral immunization. In this study, mice were immunized intranasally with purified recombinant lipidated P2086 protein (rLP2086) adjuvanted with either CT-E29H, a genetically modified cholera toxin that is significantly reduced in enzymatic activity and toxicity or RC529-AF, a synthetic immunostimulant molecule in aqueous formulation. rLP2086-specific serum and mucosal IgG and IgA antibodies were induced. IgG antibodies reacted with whole cells of multiple st...Continue Reading

References

Nov 1, 1972·The Journal of Infectious Diseases·F A WyleJ P Lowenthal
Jun 1, 1969·The Journal of Experimental Medicine·I GoldschneiderM S Artenstein
Jun 1, 1969·The Journal of Experimental Medicine·I GoldschneiderM S Artenstein
Mar 19, 2003·The Journal of Experimental Medicine·Vega MasignaniMariagrazia Pizza
Mar 25, 2004·Infection and Immunity·Leah D FletcherGary W Zlotnick

❮ Previous
Next ❯

Citations

Dec 24, 2008·The Journal of Biological Chemistry·Alessandro MascioniDésirée H H Tsao
Jun 5, 2007·Expert Review of Vaccines·Maria Leonor Sarno OliveiraPaulo Lee Ho
Jun 3, 2009·Expert Review of Vaccines·Susan LewisAndrew J Pollard
Oct 11, 2008·Expert Review of Vaccines·Ulrich Baumann
Dec 14, 2011·Journal of Reproductive Immunology·Rajesh K Naz
Jul 2, 2011·The Lancet Infectious Diseases·Mona HedayatNima Rezaei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Meningitis (ASM)

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Bacterial Meningitis

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.